Conventional versus drug-eluting bead transarterial chemoembolization:A better option for treatment of unresectable hepatocellular carcinoma

• 作者: Murtuza Razi Gu Jianping He Xu Mohammed Jameeluddin Ahmed
• 来源期刊: 介入医学杂志（英文）
• 年，卷（期）: 2021,（1）
• 所属期刊栏目: Clinical Study
• 页码范围: 11-14
• 页数: 4页
• 语种: 中文

摘要

Transarterial chemoembolization(TACE)is a minimally invasive procedure involving intra-arterial catheter-based chemotherapy to selectively administer high doses of cytotoxic drugs to the tumor bed along with ischemic ne-crosis induced by arterial embolization.Chemoembolization forms the essential core of management in patients with hepatocellular carcinoma(HCC)who are not suitable for curative therapies such as transplantation,resec-tion,or percutaneous ablation.TACE of hepatic cancer(s)has proven to be helpful in achieving local tumor control,and has supported the ability to prevent tumor progression,prolong patient life,and manage patient symptoms.Recent data have demonstrated that,in patients with single-nodule HCC≤3 cm without vascular invasion,the 5-year overall survival with TACE was found to be comparable with hepatic resection and radio-frequency ablation.Used for several years,Lipiodol continues to play a vital role as a tumor-seeking and radi-opaque drug delivery vector in interventional oncology.Efforts have been made to enhance the administration of chemotherapeutic agents to tumors.Compared with conventional TACE,drug-eluting bead TACE is a fairly new drug delivery embolization technique that permits fixed dosing and has the ability to provide sustained release of anticancer agents over a period of time.The present review discusses the basic procedure of TACE and its properties,and the effectiveness of conventional and drug-eluting bead chemoembolization systems currently available or presently undergoing clinical evaluation.